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Abstract
Myostatin is well established as a negative regulator of skeletal muscle growth, but its role in the heart is controversial. Our
goal in this study was to characterize myostatin regulation following cardiomyocyte stress and to examine the role of
myostatin in the regulation of cardiomyocyte size. Neonatal cardiomyocytes were cultured and stressed with phenylephrine.
Adenovirus was used to overexpress myostatin or dominant negative myostatin in culture. Adeno-associated virus was used
to overexpress myostatin or dominant negative myostatin in mice. Myostatin is upregulated following cardiomyocyte stress
in an Erk-dependent manner that is associated with increased nuclear translocation and DNA binding activity of MEF-2.
Myostatin overexpression leads to decreased and myostatin inhibition to increased cardiac growth both in vitro and in vivo
due to modulation of Akt and NFAT3 pathways. Myostatin is a negative regulator of cardiac growth, and further studies are
warranted to investigate the role of myostatin in the healthy and failing heart.
Citation: Bish LT, Morine KJ, Sleeper MM, Sweeney HL (2010) Myostatin Is Upregulated Following Stress in an Erk-Dependent Manner and Negatively Regulates
Cardiomyocyte Growth in Culture and in a Mouse Model. PLoS ONE 5(4): e10230. doi:10.1371/journal.pone.0010230
Editor: Carles Lalueza-Fox, Institute of Evolutionary Biology (CSIC-UPF), Spain
Received September 27, 2009; Accepted March 29, 2010; Published April 19, 2010
Copyright:  2010 Bish et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Institutes of Health (P01-HL059407 to H.L.S., U54-AR052646 to H.L.S., T32-HL-007748 to L.T.B.); and by the
Parent Project Muscular Dystrophy (to H.L.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: bish@mail.med.upenn.edu
Introduction
Myostatin, a member of the TGF-b family, is a well-established
negative regulator of skeletal muscle mass. Myostatin is synthe-
sized as a 376 amino acid pre-propeptide [1]. Once the 24 amino
acid signal sequence is cleaved, the remaining full length myostatin
contains a 242 amino acid propeptide domain and a 110 amino
acid C-terminus domain. The propeptide domain is inhibitory,
while the C-terminal domain is the active region of the peptide.
The C-terminal domain contains 9 cysteine residues critical for
dimerization, and it is this homodimer that is the active protein.
Myostatin undergoes extensive post-translational modification.
After translation, disulfide bonds form in both the propeptide and
C-terminal regions to create a homodimer. In vitro evidence
suggests that it is then cleaved by a paired dibasic amino acid
cleavage enzyme (PACE)/furin serine protease at its RSRR (aa
263–266) sequence to produce an N-terminal propeptide region
and a C-terminal region [2]. The propeptide continues to associate
non-covalently with the C-dimer, locking it in an inactive form.
This inactive, or latent, complex, composed of propeptide and C-
dimer, is then secreted into circulation. In vitro evidence suggests
that BMP-1/tolloid matrix metalloproteases can cleave the
propeptide at D76 [3]. Once cleaved, the propeptide degrades,
and the active C-dimer is released to bind its receptor, which
initiates intracellular Smad phosphorylation and activation [4].
Recent evidence also suggests that full-length myostatin can be
secreted and activated locally in the extracellular matrix [5].
The myostatin knockout mouse exhibits a 2–3 fold increase in
skeletal muscle mass due to a combination of hyperplasia and
hypertrophy [6]. This phenotype has led to the widely accepted
conclusion that myostatin acts as a chalone, a negative growth
regulator secreted by the tissue on which it acts, to inhibit skeletal
muscle growth. This conclusion has been supported by several
other studies in normal [7,8,9,10,11,12,13,14,15] and dystrophic
mice [16,17,18,19,20,21] as well as by the double-muscled Belgian
Blue and Piedmontese cattle breeds [22], which harbor a naturally
occurring mutation in the myostatin gene. Mutations leading to
double muscling have also been reported in Texel sheep and
whippets [23]. In addition, a human case has been reported in
which a splicing mutation in the myostatin gene has led to
increased muscle mass [24].
These previous studies all describe the role of myostatin in skeletal
muscle. Sharma et al. was the first group to report myostatin
expression in the heart usingboth RT-PCR and Westernblot [25]. In
addition, in a sheep model of myocardial infarction, the same group
demonstrated that myostatin protein is upregulated for up to one
month following infarct with a peak occurring at one week. In
humans, it has also been reported that myostatin activation is
increased in the myocardium of patients in heart failure and that
circulating myostatin is increased in the serum of patients in heart
failure compared to healthy controls [26].
In vitro, it was found that myostatin is upregulated following the
cyclic stretch of cardiomyocytes. Shyu et al. have demonstrated
that IGF-1, myostatin, and p38 phosphorylation increase subse-
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myostatin did not increase if IGF-1 and/or p38 signaling was
blocked before the stretch stimulus. This suggests that following a
hypertrophic stimulus, IGF-1 is secreted to stimulate cell growth.
Thereafter, however, myostatin may be secreted to negatively
regulate this growth as part of a feedback loop.
Recently, several studies have examined the role of myostatin in
cardiac growth and hypertrophy. Myostatin expression seems to
be dynamically regulated during embryonic and neonatal
development such that low expression corresponds with a high
proliferative index [28]. In addition, cardiac expression of
myostatin is upregulated during both physiologic hypertrophy
[29] and pathologic hypertrophy [30] in the rat, supporting the
involvement of myostatin in a negative feedback loop that controls
cardiac size. However, manipulation of myostatin expression in
transgenic and knockout mice has generated conflicting results.
Although investigators seem to agree that myostatin transgenic
mice have smaller hearts [31,32], myostatin knockout mice have
been reported to have larger hearts [32], smaller hearts [33],
smaller hearts that exhibit an increased hypertrophic response
[34], or normal hearts [35].
As a result, the role of myostatin in the regulation of cardiac size
remains unclear. This information is especially important in light
of the ongoing clinical trials using myostatin inhibition via an
antibody approach as a potential treatment for several types of
muscular dystrophy [36]. Since many of these patients can be
expected to experience some form of cardiomyopathy in the
future, it is important to discern how myostatin inhibition will
impact the injured heart.
With this clinical consideration in mind, the present study was
undertaken to investigate the regulation and function of myostatin
in the heart. In the first arm of the study, we used phenylephrine
(PE) to stress neonatal cardiomyocytes in culture. PE, an a-agonist,
has been previously used as a cardiac stressor to evaluate
myostatin signaling in the heart [34]. Our goals were 1.) to
identify growth pathways activated by PE stress, 2.) to quantify
myostatin activation following cardiac stress, and 3.) to use small
molecule inhibitors of each activated growth pathway to identify
possible upstream regulators of myostatin. Based on data from the
previous cardiac report and from others in skeletal muscle, we
chose to evaluate the following growth pathways: Akt and its
downstream target GSK-3b, Erk, and NFAT3 [37,38,39,40]. We
also investigated the role of the transcription factor MEF-2 in
myostatin regulation based on data reporting that the myostatin
promoter contains a MEF-2 binding domain [41]. Akt, GSK-3b,
and Erk, and MEF-2 are activated by phosphorylation, while
NFAT is activated by dephosphorylation.
In the second arm of the study, we used adenovirus in culture to
manipulate myostatin expression both positively and negatively
and examined the effect on cell size, number, and activation of the
same key growth pathways. Finally, we used adeno-associated
virus in mice to manipulate myostatin expression both positively
and negatively and examined the effect on cardiac size, function,
and signaling through the same key growth pathways.
Results
Effect of phenylephrine (PE) on growth pathway
activation, cell size, and cell number in neonatal
cardiomyocytes (NCM)
PE is a cardiac stressor, and it was hypothesized that PE stress will
activate important growth and stress pathways in the heart, including
Akt,NFAT3,and Erk. This will be followed by an increase in cell size
and possibly number. To test this hypothesis, NCM’s were stressed
with PE over a time course of 0–60 minutes to examine activation of
signaling pathways. Cell size and number were assessed after
18 hours of PE stress. As shown in Figures 1A–D, PE stress did
indeed activate Akt (and downstream GSK3- b),NFAT3, and Erk by
15 minutes. (NFAT is activated by dephosphorylation, while the
others are activated by phosphorylation.) PE had no effect on cell
number (Fig. 1E), but induced an approximately 20% increase in cell
size (Fig. 1F). Western blots from control cells which received fresh
media only (no PE) during the 60 minute time course revealed that
media alone did not induce significant activation of the growth
pathways examined (Fig. 2A–D). These data establish that PE is an
effective cardiac stressor.
Effect of PE on myostatin expression and activation in
NCM’s
It was hypothesized that myostatin expression and activation are
increased during the hypertrophic response in the heart in an
effort to exert negative feedback on cardiac growth. To test this
hypothesis, the hypertrophic response was modeled in vitro by
treating cultured NCM’s with PE as above, and levels of myostatin
precursor protein and activated myostatin were analyzed. As
shown in Figure 3A, there was no significant increase in myostatin
precursor protein from 0–60 minutes, but precursor was increased
by 18 hours. Myostatin activation was increased by 60 minutes,
and this effect was sustained through 18 hours (Fig. 3B). A
representative Western blot is shown in Figure 3C. Since
myostatin signals through the Smad pathway, the increased Smad
phosphorylation that was observed at 60 minutes confirms the
increase in myostatin activation (Figure 3D). These data indicate
that myostatin is upregulated following PE stress.
Myostatin regulation in NCM’s
PE stress stimulates the hypertrophic response and activates
growth and stress pathways in NCM’s. This is accompanied by an
increase in myostatin precursor protein and activated myostatin,
which may exert negative feedback on the growth program. If the
increase in myostatin is viewed as a response to stress, then it may
be dependent on activation of stress and/or growth pathways. To
test this hypothesis, NCM’s were pretreated with small molecule
inhibitors prior to PE stress to block activation of key growth and
stress pathways in the heart, including PI3K-Akt, p38, Erk, and
calcineurin-NFAT. Erk inhibition robustly blocked the upregula-
tion of myostatin previously observed after 18 hours of PE stress
(Fig. 4A), suggesting that Erk regulates myostatin expression
following stress in NCM’s. This finding was confirmed by
repeating the assay with only the Erk inhibitor (Fig. 4B).
Since MAPK’s have been shown to phosphorylate and activate
the transcription factor MEF-2 [42] and since the myostatin
promoter contains a MEF-2 responsive site [41], it was
hypothesized that Erk regulates myostatin by phosphorylating
MEF-2 and inducing nuclear translocation. Western blot of
nuclear extracts from the inhibition assay demonstrate that
increased MEF-2 is translocated to the nucleus following PE
stress and that this effect is blocked by pretreatment with the Erk
inhibitor (Fig. 4C). In addition, electrophoretic mobility shift assay
(EMSA) results indicate that MEF-2 DNA binding activity is
increased in nuclear extracts following PE stress, an effect that is
also blocked by pretreatment with the Erk inhibitor (Fig. 4D).
Effect of myostatin inhibition and overexpression on
NCM size and number
If myostatin is a negative regulator of NCM growth and
proliferation, myostatin overexpression should decrease cell size
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and number. To test this hypothesis in vitro, NCM’s were
transfected with adenovirus expressing the following transgenes:
LacZ (control), dominant negative myostatin (dnMSTAT), or
myostatin (MSTAT) in the presence or absence of PE stress for
18 hours. A media only control was also performed to control for
viral effects. Adenovirus mediated transfection of NCM’s was very
efficient. Figure 5A shows virtually 100% efficient cardiomyocyte
transfection with the LacZ vector. Figure 5B demonstrates that the
myostatin inhibitor (propeptide or dnMSTAT) is expressed in high
levels in the NCM’s and secreted into the media following
transfection. Figure 5C confirms high level expression of myostatin
precursor protein and biologically active C-dimer (and reduced C-
monomer) compared to control following transfection.
Samples from myostatin knock out mouse (MSTN KO) heart and
skeletal muscle, as well from normal mouse (C57) skeletal muscle,
were run alongside the cell culture samples to determine the
specificity of the antibodies. As demonstrated in Figure 5B, the
propeptide antibody did not detect any bands in the mouse sample,
despite equal protein loading (actin blot). This may reflect differential
antibody affinity in rat cardiomyocytes vs. in vivo murine samples.
However, bands of the expected sizes were detected in the cell culture
samples: the 37 kDa propeptide band in the dnMSTAT sample and
the 50 kDa myostatin precursor protein band in all lanes, with
overexpression in the MSTAT sample.
Figure 5C shows that the C-terminus antibody detected the
50 kDA myostatin precursor protein band in all culture samples, with
overexpression in the MSTAT sample. This band is absent in the
Figure 1. PE induces activation of growth and stress pathways and leads to increased growth in NCM’s. Cardiomyocytes were isolated
from neonatal rats and grown to confluency. Cells were then stressed with PE (100 uM) or fresh media only (control) for up to 60 minutes to assess
activation of growth and stress pathways. Cells were stressed for 18 hours for assessment of growth and proliferation. Each condition was tested
n=4 times. *p,0.05 vs. 0 min (ANOVA). Phospho-specific Western blots were performed to probe the activation states of (A) Akt (60 kDa) (B) GSK3-b
(46 kDa) (C) NFAT3 (ranges from approximately 90–140 kDa, depending on phosphorylation state, [59]) and (D) Erk (42 and 44 kDa). For Akt, GSK3-b,
and Erk, phosphorylation does not induce a significant increase in molecular weight; therefore, Western blots were probed with the phospho-specific
antibody, stripped, and reprobed for total protein. Both blots are shown below each graph. (P= phospho, T=total, for each protein.) For NFAT,
phosphorylation does induce a significant change in molecular weight and gel shift, so only one Western blot is demonstrated for this protein. (E) Cell
number was counted in 3 fields for each treatment, and (F) cell surface area was quantified in 3 fields using Fovea Pro software after laminin staining.
Approximately 500–800 cells were counted per condition. The plot represents mean 6 standard deviation. Representative NCM’s 18 hrs following PE
stress or control are displayed. Scale bar represents 200 mm. Magnification is 40X.
doi:10.1371/journal.pone.0010230.g001
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longerexposure,the C-dimer(,25 kDa) and monomer (,12.5 kDa)
bands become apparent in the MSTAT sample. The C-terminus
antibody did not detect bands in the skeletal muscle samples despite
equal protein loading (actin blot), perhaps due to differential affinity
of the antibody in heart vs. skeletal muscle samples.
Figure 5C also demonstrates that myostatin precursor protein is
the predominant form of myostatin present compared to C-dimer.
This phenomenon has been reported in cardiomyocyte culture
previously [43]. Nuclear translocation (Fig. 5D) of Smad was
decreased with myostatin inhibition and increased with myostatin
overexpression.
Figure 6A shows that cell number is increased by approximately
15% with myostatin inhibition and decreased by approximately
20% with myostatin overexpression. PE had no effect on cell
proliferation in the control and myostatin inhibition groups but
countered the decrease in proliferation observed with myostatin
overexpression. Figure 6B demonstrates that myostatin inhibition
induced an approximately 20% increase in cell size, while
myostatin overexpression resulted in an approximately 20%
decrease in cell size. PE stress induced an increase in cell size in
controls with a magnitude similar to that observed with myostatin
inhibition, but was not additive to the effect of myostatin
inhibition. However, myostatin overexpression blocked PE-
induced cell growth. These data indicate that myostatin negatively
regulates NCM proliferation and size.
Effect of myostatin inhibition and overexpression on
signal transduction through growth pathways in NCM’s
Myostatin may negatively regulate NCM growth by blocking
signaling through cardiac growth pathways. To test this hypothesis in
vitro, NCM’s were transfected with adenovirus expressing LacZ,
dnMSTAT, and MSTAT as previously described, then stressed with
PE or media control for 15 minutes. Phosphorylation states of key
signaling proteins (Akt, NFAT3) were evaluated. Myostatin inhibition
caused increased activation of Akt and NFAT3 (activated by
dephosphorylation) compared to LacZ control, while myostatin
overexpression caused decreased activation of Akt and NFAT3
Figure 2. Control Phospho-Western blots. Cardiomyocytes were isolated from neonatal rats and grown to confluency. These control NCM’s
were grown alongside the NCM’s undergoing PE stress but received fresh media only (no PE) during the 60 minute time course. Phospho-specific
Western blots were performed to assess the activation states of (A) Akt, (B) GSK3-b, (C) NFAT3, and (D) Erk. No significant differences were observed
following the addition of fresh media without PE. Each condition was tested n=4 times.
doi:10.1371/journal.pone.0010230.g002
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Akt and NFAT3 in LacZ-treated NCM’s to levels similar to those
observed with myostatin inhibition but had no additive effect in
dnMSTAT-treated cells (Fig. 7A, B). Myostatin overexpression
blocked PE-induced activation of Akt (phosphorylation) and NFAT3
(dephosphorylation) (Fig. 7A, B). These results support the hypothesis
that myostatin regulates NCM growth by blocking activation of
growth pathways.
Effect of myostatin inhibition and overexpression on
cardiac growth in vivo
It is hypothesized that myostatin negatively regulates cardiac
growth. To test this hypothesis in vivo, neonatal C57 mice were
injected with adeno-associated virus (AAV9) expressing the
following transgenes: LacZ (control), dominant negative myostatin
(dnMSTAT), or myostatin (MSTAT), and followed for 6 and 12
weeks. A saline injection group was used to control for viral effects.
Efficiency of transgene expression was very high. B-galactosi-
dase histochemistry demonstrates that the transgene is distributed
throughout the heart in nearly 100% of the cardiomyocytes
(Fig. 8A). Western blot demonstrates expression of dominant
negative myostatin (37 kDa) (Fig. 8B) and myostatin (precursor at
,50 kDa and C-dimer and monomer at ,25 kDa and ,13 kDa,
respectively) (Fig. 8C) and confirms decreased and increased Smad
phosphorylation with myostatin inhibition and overexpression,
respectively (Fig. 8D). Myostatin precursor was overexpressed at
approximately 10 fold the baseline level of expression detected in
the Saline, LacZ, and dnMSTAT groups (Fig. 8E).
Samples from myostatin knock out mouse (MSTN KO) heart
and skeletal muscle, as well from normal mouse (C57) skeletal
muscle, were run alongside the experimental samples to determine
the specificity of the antibodies. The propeptide antibody (Fig. 8B)
only detected the 37 kDa propeptide band that was overexpressed
in the dnMSTAT sample. No bands (myostatin precursor protein
or otherwise) were apparent in the other lanes, suggesting that this
antibody has relatively low affinity for endogenous murine
myostatin. The actin blot demonstrates equal protein loading.
The C-terminus antibody (Fig. 8C) was relatively non-specific in
the murine samples. Multiple bands are present in both
experimental and MSTN KO lanes, suggesting that these bands
are non-specific. However, the 50 kDa myostatin precursor
protein band was present at low levels in the Saline, LacZ, and
dnMSTAT lanes with 10 fold overexpression (Fig. 8E) in the
MSTAT lane. This band was absent in the MSTAT KO lanes,
confirming its specificity as the myostatin precursor protein. With
longer exposure, bands at ,25 kDa (the lighter band just above
the strong non-specific band detected in all cardiac sample,
including the MSTN KO sample) and ,13 kDa become apparent
in the MSTAT sample (Fig. 8C), which correspond to myostatin
C-dimer and monomer, respectively. Bands of corresponding size
are found in the normal (C57) mouse skeletal muscle sample but
not the MSTN KO samples, suggesting that they are specific
myostatin bands. It should also be noted that a diffuse, artifactual
band appears in the MSTN KO heart lane at a level just above the
,13 kDa C-monomer band in the MSTN and C57 skeletal
muscle lanes. The diffuse appearance of this band and the fact that
it runs slightly higher than the proposed C-monomer bands in the
MSTN and C57 skeletal muscle lanes suggests that is it not a
myostatin related band. Figure 8C also demonstrates that the
major form of myostatin present in the heart is the precursor
protein (50 kDa), while the major form of myostatin in skeletal
Figure 3. PE increases myostatin translation and activation in NCM’s. Cardiomyocytes were isolated from neonatal rats and grown to
confluency. Cells were then stressed with PE (100 uM) or media only (control) for up to 18 hours. Each condition was tested n=4 times. *p,0.05 vs.
0 min (ANOVA). Western blot was performed using the C-terminal antibody to assess levels of (A) myostatin precursor and (B) active myostatin. (C) A
representative myostatin blot is depicted. Predicted molecular weights for the various forms of myostatin are as follows: full length precursor
monomer (43–45 kDa); propeptide (30–32 kDa); C-terminus monomer (12–13 kDa); active C-dimer (24–26 kDa). Glycosylation may cause these forms
to run approximately 5–10 kDa higher than predicted on PAGE. (D) Phospho-specific Western blot was performed to assess activation of Smad
(58 kDa).
doi:10.1371/journal.pone.0010230.g003
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little precursor protein present.
At 6 weeks, myostatin inhibition induced an approximately
15% increase in relative cardiac mass (heart to body) compared
to control (Fig. 9A). Myostatin overexpression had no effect at 6
weeks (Fig. 9A). At 12 weeks, myostatin inhibition induced an
approximately 20% increase in relative cardiac mass compared
to control, and myostatin overexpression induced an approx-
imately 20% decrease in relative cardiac mass (Fig. 9B). These
data support a role for myostatin in the control of cardiac mass
in vivo.
Cardiomyocyte size was increased by approximately 20% in
the myostatin inhibition group, while size was decreased by
approximately 20% in the myostatin overexpression group at 12
weeks (Fig. 9C). This suggests that alterations in cardiac mass
were primarily due to changes in cell size and not number in our
model.
Effect of myostatin inhibition and overexpression on
cardiac function
Neither myostatin inhibition nor myostatin overexpression had
any effect on cardiac function of C57 mice as measured by 2-D
echocardiography (Table 1).
Effect of myostatin inhibition and overexpression on Akt
and NFAT3 activity
Myostatin may negatively regulate NCM growth by blocking
signaling through cardiac growth pathways. Western blot performed
on cardiac tissue lysates demonstrates that Akt and NFAT3 activity
(decreased by phosphorylation) are increased in mice in the myostatin
inhibition group and decreased in mice in the myostatin overexpres-
sion group (Fig. 10A, B). This data confirms our findings in NCM
culture that myostatin can regulated cardiac growth by modulating
signaling through Akt and NFAT3.
Figure 4. Myostatin upregulation following PE stress is Erk dependent via MEF-2. Cardiomyocytes were isolated from neonatal rats and
grown to confluency. Cells were treated with small molecule inhibitors of PI3K (wortmannin, 5 nM), p38 (SB203580, 3 uM), Erk (PD98059, 50 uM),
calcineurin (cyclosporine, 1 uM), or control 1 hour prior to 18 hours of PE stress (100 uM) and compared to baseline (no PE, no inhibition). Each
condition was tested n=4 times. (A) Western blot was performed to assess expression of the myostatin precursor protein using the C-terminus
antibody. (B) The assay was repeated with the Erk inhibitor once it was identified as being the most potent inhibitor of myostatin expression to
confirm results. (C) Western blot was performed on nuclear extracts to assess the levels of nuclear MEF-2. (D) EMSA was performed to assess MEF-2
DNA binding activity in nuclear extracts. #p,0.05 vs. PE (ANOVA); *p,0.05 vs. Con (ANOVA).
doi:10.1371/journal.pone.0010230.g004
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Myostatin is a negative regulator of skeletal muscle mass, but its
role in cardiac physiology is much less clear. Since it is expressed in
the heart, it has been suggested that myostatin may perform a
similar function there [25]. In this study, we report data to support
the hypothesis that myostatin is upregulated in response to cardiac
stress as part of a negative feedback loop to control the
hypertrophic response. This response appears to be Erk depen-
dent. In addition, our data support the hypothesis that myostatin
negatively regulates cardiac growth by modulating signaling
through the cardiac growth pathways Akt and NFAT. A detailed
model is depicted in Figure 11.
In the first set of experiments, we established that PE is an
effective cardiac stressor in vitro. Treatment of NCM’s with PE
resulted in activation of growth (Akt/GSK3-b, NFAT) and stress
(Erk) pathways. This was accompanied by an increase in cell size
but not cell number. Similar results have been observed following
PE stress of NCM’s [34].
We next examined myostatin expression and activation
following PE stress in NCM culture. PE stress induced activation
of myostatin by 60 minutes, and by 18 hours, levels of myostatin
precursor protein were also increased. Since myostatin is a TGF-b
family member known to signal through the Smad pathway [4],
we confirmed myostatin activation by documenting Smad
phosphorylation. However, it should be noted that upregulation
of other TGF-b family members during cardiac stress may also
contribute to the observed increase in Smad phosphorylation, as it
has been previously reported that ligands other than myostatin can
signal through the ‘‘myostatin’’ receptor (ActIIBR) [7]. Myostatin
upregulation has also been observed following cyclic stretch of
NCM’s [27] and treatment of NCM’s with angiotensin-II [42,43].
Myostatin may be upregulated to exert negative feedback on the
growth response initiated by these stressors [44].
Figure 5. Myostatin manipulation in NCM culture. Cardiomyocytes were isolated from neonatal rats and grown to confluency. Cells were
treated with Ad-CMV-LacZ (control), Ad-CMV-dnMSTAT, or Ad-CMV-MSTAT at MOI=100 for 18 hours in the presence or absence of PE stress
(100 uM). A media only control was also performed to control for viral effects. Each condition was tested n=4 times. (A) X-gal histochemistry
demonstrates high efficiency of adenovirus transfection. Scale bar represents 200 mm (lo) or 40 mm (hi). Western blot was performed to confirm
expression of (B) dnMSTAT (propeptide antibody) and (C) MSTAT (C-terminus antibody). Samples from myostatin knock-out (MSTN KO) mouse heart
and skeletal muscle, as well as from normal (C57) mouse skeletal muscle were also run as controls. Predicted molecular weights for the various forms
of myostatin are as follows: full length precursor monomer (43–45 kDa); propeptide (30–32 kDa); C-terminus monomer (12–13 kDa); active C-dimer
(24–26 kDa). Glycosylation may cause these forms to run approximately 5–10 kDa higher than predicted on PAGE. (D) Western blot was performed
on nuclear extracts to quantify the levels of nuclear Smad2/3. *p,0.05 vs. Media and LacZ (ANOVA).
doi:10.1371/journal.pone.0010230.g005
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stress may be dependent on upstream activation of growth and/or
stress pathways. Our data demonstrate that blocking Erk
activation with a small molecule inhibitor prior to PE stress blocks
the previously observed increase in myostatin expression. There-
fore, it appears that myostatin upregulation following PE stress is
Erk dependent. In this context, myostatin may be viewed as part of
the cell’s response to stress. To our knowledge, this is the first
report of Erk-mediated regulation of myostatin in the heart. In
addition, since previous studies have reported that myostatin
regulation following either IGF-1 or angiotensin-II stress of
NCM’s is p38 dependent [27,43], myostatin regulation following
cardiac stress may be stressor-specific.
Since myostatin has a MEF-2 responsive element in its
promoter [41] and since MAPK’s are known to phosphorylate
and activate MEF-2 [42], Erk may regulate myostatin via MEF-2
activation. We observed that both nuclear translocation and DNA
binding activity of MEF-2 are increased following PE stress and
that these effects are blocked by pretreatment of NCM’s with an
Erk inhibitor prior to PE stress. This supports our hypothesis that
Erk mediates an increase in myostatin expression via increased
MEF-2 activity. MEF-2 has been implicated in the regulation of
myostatin in NCM’s following other means of stress, including
stretch [27] and AT-II [43], and in vivo following induction of an
aorta-caval shunt [27]. However, since the degree of inhibition of
MEF-2 DNA binding activity following Erk inhibition is relatively
small compared to the inhibition of myostatin expression, other
transcription factors likely contribute to the regulation of
myostatin expression in addition to MEF-2. Further investigation
is needed to identify these factors.
In the next set of experiments, we tested the hypothesis that
myostatin negatively regulates cardiomyocyte size by modulating
signaling through growth pathways. NCM’s were treated with
adenovirus expressing dnMSTAT, MSTAT, or LacZ and then
Figure 6. Myostatin negatively regulates NCM growth and proliferation. Cardiomyocytes were isolated from neonatal rats and grown to
confluency. Cells were treated with Ad-CMV-LacZ (control), Ad-CMV-dnMSTAT, or Ad-CMV-MSTAT at MOI=100 for 18 hours in the presence or
absence of PE stress (100 uM). Each condition was tested n=4 times. (A) Cell number was counted at 40X in 3 fields for each treatment. (B) NCM
surface area was quantified in 3 fields at 40X using Fovea Pro software after laminin staining, and representative images are displayed. Approximately
500–800 cells were counted per condition. *p,0.05 vs. LacZ Con (ANOVA).
doi:10.1371/journal.pone.0010230.g006
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that was used to inhibit myostatin is a modified form of Myostatin
Belgian Blue, named after the bovine strain harboring this
mutation. This construct acts as a dominant negative because
the Belgian Blue mutant contains an 11 bp deletion that causes a
premature stop in the C-terminus, leaving only the inhibitory
propeptide to be expressed [22]. In addition, it contains a D76A
mutation, which makes the inhibitory propeptide resistant to
proteolysis [3]. In effect, this construct is a protease-resistant
propeptide that can bind to and inhibit endogenous myostatin by
preventing receptor binding [1].
We observed that myostatin inhibition induced an approxi-
mately 20% increase in cardiomyocyte size, similar to what has
been reported by another investigator [34]. PE stress induced a
similar increase in size in LacZ treated cells, but did not augment
growth in dnMSTAT treated cells. These data suggest that
myostatin and PE may exert effects on cardiomyocyte size by
modulating signaling through the same pathways, albeit in
opposite directions. For example, myostatin may inhibit a specific
pathway, while PE may activate it. The absence of an additive
increase in cell size with the combination of PE stress and
myostatin inhibition may indicate that our potent, protease-
resistant myostatin inhibitor and PE stress independently achieved
maximal pathway activation at the doses administered. In that
case, no further activation or increase in size would be possible
when both treatments were combined. Conversely, myostatin
overexpression induced an approximately 20% decrease in
cardiomyocyte size and blocked the hypertrophic response to
PE. Taken together, these data strongly support the hypothesis
that myostatin is a negative regulator of cardiomyocyte size.
We also observed that myostatin inhibition promoted NCM
proliferation and that myostatin overexpression blocked NCM
proliferation. Data from other investigators suggests that myostatin
regulates cardiomyocyte proliferation by targeting the cell cycle
proteins p21 and cdk2 [28,32]. Further investigation is needed in
our model to confirm these results.
In the next line of experiments, we sought to identify the
pathways with which myostatin may cross-talk to regulate
cardiomyocyte size. Since our data suggested that myostatin may
interact with the same pathways as PE, we investigated two
pathways that were activated by PE in our model: Akt and
NFAT3. We found that myostatin inhibition resulted in increased
activation of Akt and NFAT3, while myostatin overexpression
caused decreased activation of Akt and NFAT3. Similar to was
observed with cardiomyocyte size, PE stress did not induce
additional activation of Akt and NFAT3 in combination with
Figure 7. Myostatin negatively regulates NCM growth and proliferation by modulating signaling through Akt and NFAT3. NCM’s
were cultured as described above. Cells were treated with Ad-CMV-LacZ (control), Ad-CMV-dnMSTAT, Ad-CMV-MSTAT at MOI=100 for 18 hours, then
stressed with PE (100 uM) for 0 or 15 minutes. Each condition was tested n=4 times. Phospho-specific Western blot was performed to assess the
activation states of (A) Akt and (B) NFAT3. *p,0.05 vs. LacZ Con (ANOVA).
doi:10.1371/journal.pone.0010230.g007
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induced activation of these pathways. These data suggest that
myostatin may negatively regulate cell size by blocking activation
of Akt and NFAT3 in cardiomyocytes. It has been previously
reported that myostatin can modulate Akt signaling in NCM’s
[34], perhaps by upregulating or stabilizing PTEN [37]. Although
another group has suggested that myostatin may cross-talk with
NFAT2 in skeletal muscle [38,39], this is the first report of cross
talk between myostatin and NFAT3 pathways in cardiomyocytes.
It is possible that myostatin signaling activates kinases capable of
phosphorylating NFAT3, thus countering the effects of calci-
neurin, or it may be that mediators of myostatin signaling further
downstream can suppress calcinuerin at the transcriptional level.
Further investigation is needed to identify the link between
myostatin and NFAT3.
In the next set of experiments, we tested the hypothesis that
myostatin negatively regulates cardiac growth in vivo. AAV9 was
used to express LacZ, dnMSTAT, or MSTAT in mice, and a
saline group was added to control for viral effects. Mice were
followed for 6 and 12 weeks. AAV9 was used because it is superior
in the rodent heart compared to other serotypes [45,46,47,48].
Myostatin inhibition in the heart resulted in increased relative
cardiac mass at 6 and 12 weeks, while myostatin overexpression
resulted in decreased relative cardiac mass at 12 weeks only.
Decreased mass may not have been induced with myostatin
overexpression until 12 weeks because the myostatin protein
undergoes extensive post-translational modification before full
activity is achieved, and once active, is inhibited by several local
and circulating factors, including follistatin, FLRG, GASP-1, and
endogenous myostatin propeptide [1]. This is in contrast to the
dnMSTAT construct used in this study, which simply required
translation and secretion.
These alterations in cardiac mass were accompanied by a
corresponding increase or decrease in cardiomyocyte size and Akt
and NFAT3 activity in the myostatin inhibition and overexpres-
sion groups, respectively. These results suggest that myostatin
plays an important role in negatively regulating cardiac growth in
vivo and that it appears to do so by modulating signaling through
key cardiac growth pathways. In addition, since the alterations in
individual cardiomyocyte size were proportionally similar to the
overall alteration in total cardiac mass, it suggests that myostatin
exerted its effects primarily via hypertrophy and not via
hyperplasia in these post-natal hearts.
These data are in agreement with a recent study that reports
similar changes in cardiac size in myostatin transgenic and knock
out mice [32]. However, a controversy exists over the size of
Figure 8. Myostatin manipulation in vivo. Neonatal C57 mice (day 4–5) were treated with either Saline (n=12), AAV9-LacZ (n=11), AAV9-dnMSTAT
(n=12), or AAV9-MSTAT (n=8),via subxiphoid injection to target the heart. A saline injection group was added to control for viral effects. (A) X-gal
histochemistry demonstrates distribution of transgene expression. Western blot demonstrates expression of (B) dominant negative myostatin (propeptide
antibody), (C) myostatin precursor (,50 kDa) and processed C-monomer (,13 kDa) (C-terminus antibody), and (D) phospho-Smad2/3. Samples from
myostatin knock-out (MSTN KO) mouse heart and skeletal muscle, as well as from normal (C57) mouse skeletal muscle were also run as controls. The
precursor protein is depicted with an arrow at 50 kDa and is present at high levels in the MSTN lane and absent in the MSTN KO lanes. Proposed C-dimer
and monomer bands are also depicted with an arrow. Predicted molecular weights for the various forms of myostatin are as follows: full length precursor
monomer (43–45 kDa); propeptide (30–32 kDa); C-terminus monomer (12–13 kDa); active C-dimer (24–26 kDa). Glycosylation may causes these forms to
run approximately 5–10 kDa higher than predicted on PAGE. (E) Quantification of myostatin full-length precursor (,50 kDa). *p,0.05 vs. Saline and LacZ
(ANOVA). #p,0.05 vs. Saline, LacZ, and dnMSTAT (ANOVA). Scale bar represents 1 mm (lo) or 200 mm( h i ) .
doi:10.1371/journal.pone.0010230.g008
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size [33,34], others reporting increased size [32], and still others
reporting no effect on size [35]. This discrepancy may exist due to
the fact that the genetic background of the mice is not consistent
from study to study. It is obvious from recent studies that at least
one other unidentified factor has a significant influence on the
regulation of skeletal muscle mass since the myostatin null mouse
will experience a further increase in muscle mass if treated with
soluble activin IIB receptor [7] or crossed with a follistatin
transgenic line [49]. This unknown factor may compensate or
over-compensate for the absence of myostatin to various degrees in
different mouse strains, and this may ultimately affect cardiac size.
It should also be noted that the mice in our study are different
from the myostatin null mice described by other investigators.
Myostatin null mice never express myostatin and may experience
over-compensation of cardiac growth regulation during embryonic
and postnatal development that results in a smaller heart. Indeed,
lack of myostatin during the embryonic period may have a
permanent effect on cardiac size and/or regulation of cardiac size
since it was recently demonstrated that myostatin is dynamically
regulated during embryonic development [28]. Therefore, the
effect of myostatin knock-out may be very different from the effect
of myostatin inhibition postnatally, which is the treatment regimen
being used in the clinical trials of myostatin inhibition [36]. In
contrast, the mice in this study were treated in the postnatal
period. They experienced normal embryonic development, and
their response to myostatin inhibition during the postnatal period
was an increase in cardiac mass, supporting a role for myostatin in
negative regulation of cardiac growth in the postnatal period.
We next examined the effect of myostatin manipulation on
cardiac function by performing 2-D echocardiography at 3 months
and observed no alteration of cardiac function. This finding is in
agreement with several other studies [32,34,35]. It has been
suggested that just as in skeletal muscle, myostatin may increase
cardiac size without affecting the functional efficacy of the
contractile units [32]. Further studies are needed to evaluate the
effects of myostatin manipulation in the failing heart.
In summary, the results of this study suggest that myostatin is an
important negative regulator of cardiac growth. Myostatin is
upregulated in an Erk-dependent manner following cardiomyo-
cyte stress, and it regulates cardiac growth by modulating signaling
through important growth pathways in the heart, including Akt
and NFAT3. These findings have potential clinical implications
that mandate further investigation. Clinical trials using myostatin
Figure 9. Myostatin negatively regulates cardiac size in vivo. Neonatal C57 mice (day 4–5) were treated with either Saline, AAV9-LacZ, AAV9-
dnMSTAT, or AAV9-MSTAT via subxiphoid injection to target the heart. Mice were followed for 6 and 12 weeks, and the n for each condition is
reported on the figure. Relative heart weight is reported as the ratio of heart weight to body weight at (A) 6 weeks and (B) 12 weeks. (C)
Cardiomyocyte size at 12 weeks is reported as minimal feret’s diameter and was measured in 3 fields using Fovea Pro software 3 months following
treatment. Approximately 500–800 cells were counted per condition. *p,0.05 vs. Saline and LacZ (ANOVA). Representative images are displayed.
Scale bar represents 40 mm. Magnification is 40X.
doi:10.1371/journal.pone.0010230.g009
Table 1. Cardiac function as assessed by 2-D echocardiography at 3 months post treatment.
n HR(bpm) IVSd(cm) LVIDd(cm) LVFW(cm) LVIDs(cm) FS(%) EDV(ml) ESV(ml) EF(%) CO(L/min) SV(ml)
Saline 10 275671 0.0860.01 0.3660.03 0.0960.01 0.2160.03 3966.7 0.1260.03 0.0360.01 7567.1 0.0260.01 0.0960.02
LacZ 11 323674 0.0860.01 0.3060.04 0.0860.01 0.1860.04 4269.6 0.0860.03 0.0260.01 78610 0.0260.01 0.0660.02
dnMSTAT 8 262639 0.0860.01 0.3460.06 0.0960.01 0.2060.05 40610 0.1160.05 0.0360.02 76612 0.0260.01 0.0860.04
MSTAT 6 311699 0.0860.01 0.3560.03 0.0960.02 0.2160.04 40612 0.1160.03 0.0360.01 76613 0.0360.01 0.0960.03
p=NS for all parameters.
HR, heart rate; bpm, beats per minute; IVSd, interventricular septum in diastole; LVIDd, left ventricular inner diameter in diastole; LVFW, left ventricular free wall; LVIDs,
left ventricular inner diameter in systole; FS, fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; CO, cardiac output; SV,
stroke volume.
doi:10.1371/journal.pone.0010230.t001
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either Saline (n=12), AAV9-LacZ (n=11), AAV9-dnMSTAT (n=11), or AAV9-MSTAT (n=8) via subxiphoid injection to target the heart. Phospho-
specific Western blot was performed to determine (A) Akt activity (via GSK-3b phosphorylation) and (B) NFAT3 activity. *p,0.05 vs. Saline and LacZ
(ANOVA).
doi:10.1371/journal.pone.0010230.g010
Figure 11. Model of myostatin regulation and function in the heart. In this study, PE was used to model cardiac stress. This led to early (15
minute) activation of the cardiac growth pathways NFAT and Akt, and an increase in cell size was apparent by 18 hours. Erk was also activated early
(15 minutes), and this was shown to be necessary for subsequent MEF-2 phosphorylation and increase in myostatin expression. Myostatin was shown
to be able to exert negative feedback on growth by blocking activation of NFAT and Akt. In this model, therefore, PE activates growth via NFAT and
Akt, while at the same time activating Erk, which drives MEF-2 dependent upregulation of myostatin, which in turns exerts negative feedback on
growth by blocking NFAT and Akt activation. Further studies are needed to determine the mechanism of myostatin-mediated blockade of Akt and
NFAT activation, including whether each process is Smad independent vs. Smad dependent.
doi:10.1371/journal.pone.0010230.g011
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several types of muscular dystrophy are ongoing [36]. Since many
of these patients can be expected to experience some form of
cardiomyopathy in the future, it will be important to discern how
myostatin inhibition will impact the injured heart. If myostatin
plays a critical role in regulating cardiac remodeling following
stress, inhibition of myostatin in this population, or in any
population experiencing cardiac stress, could result in a very
deleterious outcome. Large animal studies in which myostatin is
both inhibited and overexpressed in the setting of cardiac failure
should be the next step to address these important issues.
Materials and Methods
Ethics Statement
All animals were handled in compliance with the Guide for the
Care and Use of Laboratory Animals published by the National
Institutes of Health (NIH publication No. 85–23, revised 1996). In
addition, all animal work was performed under protocols
approved by the Institutional Animal Care and Use Committee
of the University of Pennsylvania.
Vector Production
Each adenovirus vector was designed to express either full-
length murine myostatin (MSTAT), dominant negative murine
myostatin (dnMSTAT), or the LacZ reporter gene under control
of the constitutive cytomegalovirus (CMV) promoter. Vectors were
produced according to the previously described protocol by the
Vector Core of the University of Pennsylvania [50].
Each adeno-associated virus serotype 9 (AAV9) vector was
designed to express either full-length murine myostatin (MSTAT),
dominant negative murine myostatin (dnMSTAT), or the nuclear-
localized LacZ reporter gene under control of the constitutive
truncated desmin promoter with synthetic enhancer (SEDES460
promoter). Vectors were produced according to the previously
described pseudotyping protocol by the Vector Core of the
University of Pennsylvania [51].
The MSTAT transgene contains the cDNA for the entire
1131 bp murine myostatin gene encoding 376 amino acids (aa).
This includes a 24 aa signal sequence, a 242 aa inhibitory N-
terminal propeptide, and a 110 aa C-terminus, the dimer of which
is biologically active myostatin (Fig. 12A). The dnMSTAT
transgene contains the cDNA for the first 822 bp (274 aa) of the
murine myostatin gene followed by a premature stop. This is
modeled after the mutation in the double-muscled Belgian Blue
cow [52]. It also contains an A to C transition at bp 227 (D76A),
which destroys a cleavage site and confers protease resistance
(Fig. 12B) [3]. In effect, the dnMSTAT construct is a protease-
resistant inhibitory propeptide lacking the biologically active C-
terminus that is designed to inhibit endogenous myostatin.
Primary Cardiomyocyte Culture
Primary cultures of rat neonatal cardiomyocytes (NCM’s) were
prepared from Wistar rats as previously described [53]. 2610
6
cells were plated per 60 mm dish. The cardiac stress response was
induced using phenylephrine (PE) at 100 uM (Sigma, St. Louis,
MO). To determine the roles of Erk, p38, PI3K, and calcineurin in
PE-induced myostatin expression, NCM’s were pretreated for
1 hour before PE stress with the following inhibitors: 50 uM
PD98059 (Erk, Calbiochem, San Diego, CA); 3 uM SB203580
(p38, Calbiochem, San Diego, CA); 5 nM wortmannin (PI3K,
Sigma, St. Louis, MO); or 1 uM cyclosporine (calcineurin, Sigma,
St. Louis, MO). For overexpression studies, adenovirus constructs
were used at an MOI=100.
Mouse Protocol
Neonatal mice were injected with vector or saline control as
previously described [48,54,55]. Briefly, four to five day old C57/
Bl6 mice underwent cryoanesthesia, and a puncture was made at
the left costoxiphoid angle of the anterior chest with a 33 gauge
Hamilton needle. 50 uL containing 2.5610
11 genome copies of
the AAV9 vector in normal saline were then injected into the
pericardial space via this subxiphoid approach. Pups were
subsequently rewarmed under a heat lamp and returned to their
mothers for further care. At weaning, males and females were
separated, and only males continued in the study. The final n per
group ranged from 5–12 and is reported in the appropriate figure
or table legend. Euthanasia was scheduled for 6 weeks and 12
weeks.
Western Blot
Cardiac samples obtained for Western blotting were snap-
frozen in liquid nitrogen after removal from the mouse without
OCT fixative. Specimens were pulverized, homogenized in 10
volumes of triple-detergent lysis buffer [50 mM Tris, pH 8.0,
0.1% SDS, 1.0% Triton X-100, 0.5% DOC, 5 mM EDTA,
50 mM DTT, 0.4 tab/10 mL Complete protease inhibitor
(Roche, Indianapolis, IN)], and centrifuged at 13,000 rpm for 5
minutes. NCM’s were harvested in 150 uL of lysis buffer and
centrifuged as above. Protein concentration of the supernatant was
then determined using the BioRad Protein Assay (Hercules, CA).
Either 50 mg (whole cell lysate from NCM culture or intact hearts)
or 15 ug [nuclear extract from NCM culture, prepared using the
Figure 12. Schematic of domains included in each myostatin
construct. (A) The cDNA encoding full-length murine myostatin
(MSTAT) that was overexpressed from both adenovirus and AAV
vectors contained the following domains: signal sequence, propeptide
(N-terminus) containing aspartate at amino acid 76 (D76), RSRR
cleavage site, and C-terminus. Myostatin activation requires cleavage
at RSRR as an initial step to disrupt the covalent bond between the C-
terminus and the propeptide. However, the inhibitory propeptide
continues to associate with the C-terminus non-covalently, and full
activation of myostatin requires a second cleavage at D76 to free the C-
terminus from the propeptide and induce propeptide degradation. (B)
The cDNA encoding dominant negative murine myostatin (dnMSTAT)
that was overexpressed from both adenovirus and AAV vectors
contained the following domains: signal sequence, propeptide (N-
terminus) containing a D76A mutation, RSRR cleavage site, and a
truncated C-terminus resulting from a premature stop. As a result, no
full-length or active myostatin is expressed from this construct. In
contrast, a protease-resistant (D76A) inhibitory propeptide that acts in a
dominant negative manner is expressed. Corresponding amino acid
(AA) positions are indicated below each cartoon. Note that cartoon is
not to scale.
doi:10.1371/journal.pone.0010230.g012
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electrophoresed on a 4–20% SDS-polyacrylamide (Lonza, Rock-
land, ME) gel following the addition of 2X sample loading buffer
(130 mM Tris, pH=8.0, 20% glycerol, 4.6% SDS, 2% DTT,
0.02% bromophenol blue) and 5 minutes of denaturation at
100uC. Proteins were then transferred to Immobilon-P (Millipore,
Bedford, MA) using the iBlot transfer apparatus (Invitrogen,
Carlsbad, CA). The membrane was subsequently blocked with 5%
nonfat dry milk in Tris-buffered saline containing 0.05% Tween
20. Immunoblotting was performed to detect C-term myostatin
(polyclonal) (1:500, Millipore, AB3239, Temecula, CA); N-term
myostatin (polyclonal) (R&D Systems, AF1539, Minneapolis,
MN); phospho-Smad 2/3 (polyclonal) (1:500, Millipore, Teme-
cula, CA); Smad 2/3 (polyclonal) (1:1000, Cell Signaling
Technology, Danvers, MA); MEF-2 (polyclonal) (1:1000, Santa
Cruz Biotechnology, Santa Cruz, CA); phospho-Erk1/2 (poly-
clonal) and total Erk1/2 (polyclonal) (1:1000, Cell Signaling
Technology, Danvers, MA); phospho-GSK-3b (monoclonal) and
total GSK-3b (polyclonal) (1:1000, Cell Signaling Technology,
Danvers, MA); phospho-Akt (polyclonal) and total Akt (polyclonal)
(1:500, 1:1000, Cell Signaling Technology, Danvers, MA);
NFAT3 (polyclonal) (1:500, Santa Cruz Biotechnology, Santa
Cruz, CA); and actin (monoclonal) (1:2000, Sigma, St. Louis,
MO). Detection was performed using the Super Signal West Pico
Chemiluminescent Substrate kit (Pierce, Rockford, IL). Protein
bands were quantified using densitometry software (Alpha
Innotech, San Leandro, CA), and bands were normalized to the
actin band as a loading control. Phospho-protein bands were
normalized to the relevant total protein (i.e., phospho-Smad to
total Smad).
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts were prepared from NCM’s using the NE-PER
kit (Pierce, Rockford, IL). Consensus and mutant control
oligonucleotides for Smad-2 [56] and MEF-2 [43] were prepared
by Integrated DNA Technologies (Coralville, IA); biotin labeled
using the Biotin 39 End DNA Labeling Kit (Pierce, Rockford, IL),
and annealed into doubled-stranded probes for 1 hour at room
temperature. The EMSA was perfomed using the Lightshift
Chemiluminescent EMSA kit (Pierce, Rockford, IL). Briefly, 2 ug
nuclear extract were used per reaction, and reactions were
electrophoresed on a 6% DNA Retardation Gel (Invitrogen,
Carlsbad, CA) and transferred to a Biodyne B nylon membrane
(Pierce, Rockford, IL). Controls were performed with no extract,
excess unlabelled consensus probe, and excess labeled mutant
probe to assess the specificity of the assay. Specificity was also
confirmed by observing antibody-induced shift of the DNA/
protein complex.
Histology and Cardiomyocyte Size Analysis
NCM’s were fixed with 2% paraformaldehyde/0.1% glutaralde-
hyde for 5 minutes, washed in PBS, and blocked with5% BSA in PBS
for 15 minutes. Slides were incubated with an anti-laminin antibody
(1:100, Neomarkers, Fremont, CA) for 1 hour at room temperature.
Slides were washed with PBS; incubated with anti-rabbit-488 (1:200,
Invitrogen, Carlsbad, CA), then washed with PBS.
Intact hearts were frozen in OCT embedding compound
(Tissue Tek, Torrance, CA), and 10 mm cryosections were
prepared. Slides were fixed and blocked as described above; then
incubated with anti-wheat germ agglutinin-Alexa Fluor 488
conjugate antibody (1:100, Molecular Probes, Eugene, OR), and
washed in PBS.
For both, slides were mounted with Vectashield with DAPI
(Vector Laboratories, Burlingame, CA) and examined for
fluorescence using a Leitz DMRBE fluorescent microscope (Leica,
Bannockburn, IL) equipped with a Micro Max digital camera
(Princeton Instruments, Trenton, NJ) interfaced with Image Pro
Plus software (Media Cybernetics, Bethesda, MD). Three random
images were taken for each sample at 40X. The n per condition is
reported in each figure legend. Approximately 500–800 cells were
counted per condition. Surface area (NCM) or minimal Feret’s
diameter (cardiac section) were analyzed using the Fovea Pro 4.0
plug-in (Reindeer Graphics, Asheville, NC) for Photoshop
Elements 4.0 (Adobe, San Jose, CA). The minimal Feret’s
diameter is more resistant to artifactual variation in size due to
oblique vs. cross-sectional orientation of muscle fibers compared to
standard area measurements [57].
Echocardiography
M-mode echocardiography was performed on mice 3 months
after injection under ketamine/xylazine anesthesia using a 15-
MHz phased-array probe connected to a Sonos 7500 echocar-
diographic machine (Philips Medical Imaging, Andover, Massa-
chusetts). In brief, an M-mode cursor was positioned in the
parasternal short-axis view perpendicular to the interventricular
septum and posterior wall of the LV at the level of the papillary
muscles, and M-mode images were obtained for measurement of
LV end-diastolic and end-systolic dimension (LVDd and LVDs).
The percentage of fractional shortening (%FS) was calculated from
the equation %FS = [(LVDd – LVDs)/LVDd] 6100. The end
diastolic and end systolic volumes, ejection fraction, cardiac output
and stroke volume were calculated using the Teicholtz formulas
[58]. The same sonographer performed all the studies and
resulting calculations and was blinded to the treatment groups of
the mice.
Statistics
Mean values from each experimental group were compared
using the two-tailed Student’s t test or one-way ANOVA with
Student Newman-Keuls post-hoc analysis.
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